journal
MENU ▼
Read by QxMD icon Read
search

Pharmacogenomics and Personalized Medicine

journal
https://www.readbyqxmd.com/read/27853387/treatment-resistant-schizophrenia-current-insights-on-the-pharmacogenomics-of-antipsychotics
#1
REVIEW
John Lally, Fiona Gaughran, Philip Timms, Sarah R Curran
Up to 30% of people with schizophrenia do not respond to two (or more) trials of dopaminergic antipsychotics. They are said to have treatment-resistant schizophrenia (TRS). Clozapine is still the only effective treatment for TRS, although it is underused in clinical practice. Initial use is delayed, it can be hard for patients to tolerate, and clinicians can be uncertain as to when to use it. What if, at the start of treatment, we could identify those patients likely to respond to clozapine - and those likely to suffer adverse effects? It is likely that clinicians would feel less inhibited about using it, allowing clozapine to be used earlier and more appropriately...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27789970/pharmacogenetic-polymorphism-as-an-independent-risk-factor-for-frequent-hospitalizations-in-older-adults-with-polypharmacy-a-pilot-study
#2
Joseph Finkelstein, Carol Friedman, George Hripcsak, Manuel Cabrera
Pharmacogenetic testing identifies genetic biomarkers that are predictive of individual sensitivity to particular drugs. A significant proportion of medications that are widely prescribed for older adults are metabolized by enzymes that are encoded by highly polymorphic genes. Pharmacogenetic testing is increasingly used to optimize the medication regimen; however, its potential in older adults with polypharmacy has not been systematically explored. Following the initial case-series study, this study hypothesized that frequently hospitalized older adults with polypharmacy have higher frequency of pharmacogenetic polymorphism as compared to older adults with polypharmacy who are rarely admitted to a hospital...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27757045/pharmacogenomics-of-statins-understanding-susceptibility-to-adverse-effects
#3
Joseph P Kitzmiller, Eduard B Mikulik, Anees M Dauki, Chandrama Murkherjee, Jasmine A Luzum
Statins are a cornerstone of the pharmacologic treatment and prevention of atherosclerotic cardiovascular disease. Atherosclerotic disease is a predominant cause of mortality and morbidity worldwide. Statins are among the most commonly prescribed classes of medications, and their prescribing indications and target patient populations have been significantly expanded in the official guidelines recently published by the American and European expert panels. Adverse effects of statin pharmacotherapy, however, result in significant cost and morbidity and can lead to nonadherence and discontinuation of therapy...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27695358/the-correlation-between-cyp2d6-isoenzyme-activity-and-haloperidol-efficacy-and-safety-profile-in-patients-with-alcohol-addiction-during-the-exacerbation-of-the-addiction
#4
Dmitry Alekseevich Sychev, Mikhail Sergeevich Zastrozhin, Valery Valerieevich Smirnov, Elena Anatolievna Grishina, Ludmila Mikhailovna Savchenko, Evgeny Alekseevich Bryun
BACKGROUND: Today, it is proved that isoenzymes CYP2D6 and CYP3A4 are involved in metabolism of haloperidol. In our previous investigation, we found a medium correlation between the efficacy and safety of haloperidol and the activity of CYP3A4 in patients with alcohol abuse. OBJECTIVE: The aim of this study was to evaluate the correlation between the activity of CYP2D6 and the efficacy and safety of haloperidol in patients with diagnosed alcohol abuse. METHODS: The study involved 70 men (average age: 40...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27574461/comments-on-lucire-and-crotty-2011
#5
Anton Jm Loonen, Robbert-Jan Verkes
No abstract text is available yet for this article.
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27574460/use-of-combinatorial-pharmacogenomic-testing-in-two-cases-from-community-psychiatry
#6
Eve S Fields, Raymond A Lorenz, Joel G Winner
This report describes two cases in which pharmacogenomic testing was utilized to guide medication selection for difficult to treat patients. The first patient is a 29-year old male with bipolar disorder who had severe akathisia due to his long acting injectable antipsychotic. The second patient is a 59-year old female with major depressive disorder who was not responding to her medication. In both cases, a proprietary combinatorial pharmacogenomic test was used to inform medication changes and improve patient outcomes...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27471406/cancer-pharmacogenomics-challenges-in-implementation-and-patient-focused-perspectives
#7
REVIEW
Jai N Patel
Cancer pharmacogenomics is an evolving landscape and has the potential to significantly impact cancer care and precision medicine. Harnessing and understanding the genetic code of both the patient (germline) and the tumor (somatic) provides the opportunity for personalized dose and therapy selection for cancer patients. While germline DNA is useful in understanding the pharmacokinetic and pharmacodynamic disposition of a drug, somatic DNA is particularly useful in identifying drug targets and predicting drug response...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27307760/the-frequency-of-slco1b1-5-polymorphism-genotypes-among-russian-and-sakha-yakutia-patients-with-hypercholesterolemia
#8
Dmitrij Alekseevitch Sychev, Grigorij Nikolaevich Shuev, Jana Valer'evna Chertovskih, Nadezhda Romanovna Maksimova, Andrej Vladimirovich Grachev, Ol'ga Aleksandrovna Syrkova
INTRODUCTION: Statins are the most commonly prescribed medicines for treatment of hypercholesterolemia. At the same time, up to 25% of patients cannot tolerate or have to discontinue the statin therapy due to statin-induced myopathy. In a majority of cases, statin-induced myopathy is attributed to SLCO1B1 gene polymorphism. The strongest association between statin-induced myopathy and SLCO1B1 gene polymorphism was described for simvastatin. Our research was focused on the frequency of SLCO1B1*5 genetic variant in the Russian population and in the native population of Sakha (Yakutia)...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27175090/the-effect-of-abcb1-polymorphisms-on-the-outcome-of-breast-cancer-treatment
#9
REVIEW
Sonam Tulsyan, Rama Devi Mittal, Balraj Mittal
The ABCB1 gene encodes a permeability glycoprotein, which is one of the most extensively studied human adenosine-triphosphate (ATP)-dependent efflux transporters. Permeability glycoprotein is expressed in the apical membranes of tissues such as intestine, liver, blood-brain barrier, kidney, placenta, and testis and contributes to intracellular drug disposition. It is also highly expressed in tumor cells conferring drug resistance, which is one of the major problems in the efficacy of cancer chemotherapy treatment...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27143951/potential-utility-of-precision-medicine-for-older-adults-with-polypharmacy-a-case-series-study
#10
Joseph Finkelstein, Carol Friedman, George Hripcsak, Manuel Cabrera
Pharmacogenomic (PGx) testing has been increasingly used to optimize drug regimens; however, its potential in older adults with polypharmacy has not been systematically studied. In this hypothesis-generating study, we employed a case series design to explore potential utility of PGx testing in older adults with polypharmacy and to highlight barriers in implementing this methodology in routine clinical practice. Three patients with concurrent chronic heart and lung disease aged 74, 78, and 83 years and whose medication regimen comprised 26, 17, and 18 drugs, correspondingly, served as cases for this study...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27103840/pharmacogenetics-in-type-2-diabetes-influence-on-response-to-oral-hypoglycemic-agents
#11
REVIEW
Adem Yesuf Dawed, Kaixin Zhou, Ewan Robert Pearson
Type 2 diabetes is one of the leading causes of morbidity and mortality, consuming a significant proportion of public health spending. Oral hypoglycemic agents (OHAs) are the frontline treatment approaches after lifestyle changes. However, huge interindividual variation in response to OHAs results in unnecessary treatment failure. In addition to nongenetic factors, genetic factors are thought to contribute to much of such variability, highlighting the importance of the potential of pharmacogenetics to improve therapeutic outcome...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/26858530/targeted-therapies-with-companion-diagnostics-in-the-management-of-breast-cancer-current-perspectives
#12
REVIEW
Meagan B Myers
Breast cancer is a multifaceted disease exhibiting both intertumoral and intratumoral heterogeneity as well as variable disease course. Over 2 decades of research has advanced the understanding of the molecular substructure of breast cancer, directing the development of new therapeutic strategies against these actionable targets. In vitro diagnostics, and specifically companion diagnostics, have been integral in the successful development and implementation of these targeted therapies, such as those directed against the human epidermal growth factor receptor 2...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/26855597/initial-assessment-of-the-benefits-of-implementing-pharmacogenetics-into-the-medical-management-of-patients-in-a-long-term-care-facility
#13
Juan-Sebastian Saldivar, David Taylor, Elaine A Sugarman, Ali Cullors, Jorge A Garces, Kahuku Oades, Joel Centeno
The health care costs associated with prescription drugs are enormous, particularly in patients with polypharmacy (taking more than five prescription medications), and they continue to grow annually. The evolution of pharmacogenetics has provided clinicians with a valuable tool that allows for a smarter, more fine-tuned approach to treating patients for a number of clinical conditions. Applying a pharmacogenetics approach to the medical management of patients can provide a significant improvement to their care, result in cost savings by reducing the use of ineffective drugs, and decrease overall health care utilization...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/26675332/variations-in-telomere-maintenance-and-the-role-of-telomerase-inhibition-in-gastrointestinal-cancer
#14
REVIEW
Steffen Heeg
Immortalization is an important step toward the malignant transformation of human cells and is critically dependent upon telomere maintenance. There are two known mechanisms to maintain human telomeres. The process of telomere maintenance is either mediated through activation of the enzyme telomerase or through an alternative mechanism of telomere lengthening called ALT. While 85% of all human tumors show reactivation of telomerase, the remaining 15% are able to maintain telomeres via ALT. The therapeutic potential of telomerase inhibitors is currently investigated in a variety of human cancers...
2015: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/26622191/a-pharmacogenomic-prospective-randomized-controlled-trial-of-cyp2b6-polymorphisms-and-efavirenz-dose-adjustment-among-hiv-infected-thai-patients-a-pilot-study
#15
Pansachee Damronglerd, Chonlaphat Sukasem, Wilawan Thipmontree, Apichaya Puangpetch, Sasisopin Kiertiburanakul
OBJECTIVE: We aimed at comparing clinical/immunological outcomes in human immunodeficiency virus (HIV)-infected patients who were treated with CYP2B6-guided and conventional efavirenz (EFV) therapy. METHODS: This study was a 24-week prospective randomized controlled trial. Eligible patients were HIV-infected adults yet to start antiretroviral therapy. Twenty-four HIV-infected patients were recruited and randomly assigned to genotype CYP2B6 polymorphism before ART initial dose...
2015: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/26622190/personalized-treatment-options-for-alk-positive-metastatic-non-small-cell-lung-cancer-potential-role-for-ceritinib
#16
REVIEW
Hazem El-Osta, Rodney Shackelford
The fusion of echinoderm microtubule-associated protein-like 4 with the anaplastic lymphoma kinase (EML4-ALK) is found in 3%-7% of non-small-cell lung cancer (NSCLC) cases and confers sensitivity to crizotinib, the first United States Food and Drug Administration (FDA)-approved ALK inhibitor drug. Although crizotinib has an excellent initial therapeutic effect, acquired resistance to this drug invariably develops within the first year of treatment. Resistance may involve secondary gatekeeper mutations within the ALK gene interfering with crizotinib-ALK interactions, or compensatory activation of aberrant bypass signaling pathways...
2015: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/26604812/the-use-of-pharmacogenetics-in-clinical-practice-for-the-treatment-of-individuals-with-hiv-infection-in-thailand
#17
Asalaysa Bushyakanist, Apichaya Puangpetch, Chonlaphat Sukasem, Sasisopin Kiertiburanakul
OBJECTIVES: The objectives of this study were to describe the use of pharmacogenetics in clinical practice for the treatment of individuals with human immunodeficiency virus (HIV) infection and to determine the treatment outcomes of HIV-infected patients in whom pharmacogenetic testing was performed. METHODS: This study involves a retrospective collection of medical records of HIV-infected patients who attended Ramathibodi Hospital during January 2011 to November 2014 and in whom pharmacogenetic testing was performed...
2015: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/26445557/once-daily-dose-regimen-of-ribavirin-is-interchangeable-with-a-twice-daily-dose-regimen-randomized-open-clinical-trial
#18
Jiska M Balk, Guido Rmm Haenen, Özgür M Koc, Ron Peters, Aalt Bast, Wim Jf van der Vijgh, Ger H Koek
BACKGROUND: The combination of ribavirin (RBV) and pegylated interferon (PEG-IFN) is effective in the treatment of chronic hepatitis C infection. Reducing the frequency of RBV intake from twice to once a day will improve compliance and opens up the opportunity to combine RBV with new and more specific direct-acting agents in one pill. Therefore, the purpose of this study was to evaluate the pharmacokinetic profile of RBV in a once-daily to twice-daily regimen. The secondary aim was to determine tolerability as well as the severity and differences in side effects of both treatment regimens...
2015: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/26309417/olaparib-in-the-management-of-ovarian-cancer
#19
REVIEW
Kristin Bixel, John L Hays
Alterations in the homologous repair pathway are thought to occur in 30%-50% of epithelial ovarian cancers. Cells deficient in homologous recombination rely on alternative pathways for DNA repair in order to survive, thereby providing a potential target for therapy. Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, capitalizes on this concept and is the first drug in its class approved for patients with ovarian cancer. This review article will provide an overview of the BRCA genes and homologous recombination, the role of PARP in DNA repair and the biological rationale for the use of PARP inhibitors as cancer therapy, and ultimately will focus on the use of olaparib in the management of ovarian cancer...
2015: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/26309416/economic-evaluations-of-personalized-medicine-existing-challenges-and-current-developments
#20
REVIEW
Fatiha H Shabaruddin, Nigel D Fleeman, Katherine Payne
Personalized medicine, with the aim of safely, effectively, and cost-effectively targeting treatment to a prespecified patient population, has always been a long-time goal within health care. It is often argued that personalizing treatment will inevitably improve clinical outcomes for patients and help achieve more effective use of health care resources. Demand is increasing for demonstrable evidence of clinical and cost-effectiveness to support the use of personalized medicine in health care. This paper begins with an overview of the existing challenges in conducting economic evaluations of genetics- and genomics-targeted technologies, as an example of personalized medicine...
2015: Pharmacogenomics and Personalized Medicine
journal
journal
42543
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"